Eupraxia Pharmaceuticals Files 6-K Report
Ticker: EPRX · Form: 6-K · Filed: Oct 15, 2024 · CIK: 1581178
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, press-release
TL;DR
Eupraxia Pharma dropped a 6-K, check the press release for deets.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on October 15, 2024, reporting information for the month of October 2024. The filing includes a press release dated October 15, 2024, as Exhibit 99.1. The company is incorporated in Canada and its principal executive office is located in Victoria, British Columbia.
Why It Matters
This filing provides an update on Eupraxia Pharmaceuticals' regulatory reporting, which is important for investors to stay informed about the company's ongoing disclosures and compliance.
Risk Assessment
Risk Level: low — This filing is a routine report and does not contain significant new financial or operational information that would inherently increase risk.
Key Players & Entities
- EUPRAXIA PHARMACEUTICALS INC. (company) — Filer and Registrant
- October 15, 2024 (date) — Filing Date and Press Release Date
- Bruce Cousins (person) — Signatory for the filing
- 201-2067 Cadboro Bay Road Victoria, British Columbia, Canada V8R 5G4 (address) — Registrant's principal executive office
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, typically to provide information that the issuer makes public in its home country.
What specific document is included as part of this 6-K filing?
Exhibit 99.1, a Press Release dated October 15, 2024, is included as part of this report.
What is Eupraxia Pharmaceuticals Inc.'s SIC code?
Eupraxia Pharmaceuticals Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Who signed this Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.?
Bruce Cousins signed the Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.
Does Eupraxia Pharmaceuticals Inc. file annual reports under Form 20-F or Form 40-F?
Eupraxia Pharmaceuticals Inc. files annual reports under Form 40-F.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2024-10-15 08:06:29
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 20KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-001224.txt ( ) — 64KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: October 15, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer